fluorescein-5-isothiocyanate has been researched along with Pulmonary Hypertension in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, L; Egashira, K; Iwata, E; Kimura, S; Kishimoto, J; Matoba, T; Miyagawa, M; Nagaoka, K; Nakano, K; Sunagawa, K; Tsujimoto, H | 1 |
1 other study(ies) available for fluorescein-5-isothiocyanate and Pulmonary Hypertension
| Article | Year |
|---|---|
Nanoparticle-mediated delivery of pitavastatin into lungs ameliorates the development and induces regression of monocrotaline-induced pulmonary artery hypertension.
Topics: Animals; Cell Line; Cell Proliferation; Cells, Cultured; Cytokines; Dose-Response Relationship, Drug; Drug Delivery Systems; Fluorescein-5-isothiocyanate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Kaplan-Meier Estimate; Lung; Male; Microscopy, Fluorescence; Monocrotaline; Myocytes, Smooth Muscle; Nanoparticles; NF-kappa B; Nitric Oxide Synthase; Pulmonary Artery; Quinolines; Rats; Rats, Sprague-Dawley; Remission Induction | 2011 |